NCT03090516 is a Phase 2, PHASE3 clinical trial of Ginkgo biloba dispersible tablets in Alzheimer's, sponsored by The First Affiliated Hospital with Nanjing Medical University.

Who is sponsoring NCT03090516?

NCT03090516 is sponsored by The First Affiliated Hospital with Nanjing Medical University.

What drugs are being tested in NCT03090516?

Interventions in NCT03090516: Ginkgo biloba dispersible tablets, Donepezil, Ginkgo biloba dispersible tablets and Donepezil.

What condition does NCT03090516 study?

NCT03090516 studies Alzheimer's.

Is NCT03090516 still recruiting?

NCT03090516 is currently status unknown. Last updated 7 August 2019.

Last reviewed 2019-08-07 · How we verify

NCT03090516

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Efficacy of Ginkgo Biloba Extract in the Treatment of Alzheimer's Disease

Status unknown Phase 2, PHASE3 Last updated 7 August 2019

What this trial tests

Phase 2, PHASE3 trial testing Ginkgo biloba dispersible tablets in Alzheimer's in 240 participants. Status unknown.

Timeline

10 August 2016

Primary endpoint
10 March 2020

10 March 2020

Quick facts

Lead sponsor	The First Affiliated Hospital with Nanjing Medical University
Phase	Phase 2, PHASE3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	240
Start date	10 August 2016
Primary completion	10 March 2020
Estimated completion	10 March 2020
Sites	1 location across China

Drugs / interventions tested

Ginkgo biloba dispersible tablets — full drug profile →
Donepezil (DONEPEZIL) — full drug profile →
Ginkgo biloba dispersible tablets and Donepezil — full drug profile →

Conditions studied

Alzheimer's — all drugs for Alzheimer's →

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Who can join

Adults 50 to 85, any sex, with Alzheimer's. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This project explores Ginkgo biloba ester dispersible tablets influence on cognitive function in patients with mild-to-moderate elderly, to observe the effects of different intervention time on cognitive function, for alzheimer's patients in drug rehabilitation treatment provides an effective solution.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Alzheimer's disease drug development pipeline: 2019.
Cummings J, Lee G, Ritter A, Sabbagh M, et al · · 2019 · cited 485× · PMID 31334330 · DOI 10.1016/j.trci.2019.05.008
Clinical trials of new drugs for Alzheimer disease.
Huang LK, Chao SP, Hu CJ. · · 2020 · cited 426× · PMID 31906949 · DOI 10.1186/s12929-019-0609-7
Alzheimer's disease drug development pipeline: 2020.
Cummings J, Lee G, Ritter A, Sabbagh M, et al · · 2020 · cited 350× · PMID 32695874 · DOI 10.1002/trc2.12050
Alzheimer's disease drug development pipeline: 2021.
Cummings J, Lee G, Zhong K, Fonseca J, et al · · 2021 · cited 312× · PMID 34095440 · DOI 10.1002/trc2.12179
Pathological mechanisms and therapeutic strategies for Alzheimer's disease.
Ju Y, Tam KY. · · 2022 · cited 260× · PMID 34380884 · DOI 10.4103/1673-5374.320970
The Potential Use of Plant Natural Products and Plant Extracts with Antioxidant Properties for the Prevention/Treatment of Neurodegenerative Diseases: In Vitro, In Vivo and Clinical Trials.
Pohl F, Kong Thoo Lin P. · · 2018 · cited 159× · PMID 30544977 · DOI 10.3390/molecules23123283
Role of Oxidative Damage in Alzheimer's Disease and Neurodegeneration: From Pathogenic Mechanisms to Biomarker Discovery.
Buccellato FR, D'Anca M, Fenoglio C, Scarpini E, et al · · 2021 · cited 95× · PMID 34572985 · DOI 10.3390/antiox10091353
Oxidative Stress, Neuroinflammation, and NADPH Oxidase: Implications in the Pathogenesis and Treatment of Alzheimer's Disease.
Ganguly U, Kaur U, Chakrabarti SS, Sharma P, et al · · 2021 · cited 86× · PMID 33953837 · DOI 10.1155/2021/7086512

Verify or expand the search:

Other recruiting trials for Alzheimer's

Currently open trials in the same condition.

NCT05655195 — Chronic Treatment of Alzheimer's Disease by Gamma Light and Sound Therapy · NA · recruiting

Other The First Affiliated Hospital with Nanjing Medical University trials

Trials by the same sponsor.

NCT07377981 — An Exploratory Study of the Efficacy and Safety of Esketamine and Dexmedetomidine in Non-Intubated ICU Patients With Hyp · Phase 4 · not yet recruiting
NCT07523789 — Comparison of Chemotherapy and Immunotherapy in Neoadjuvant Therapy for TNBC · not yet recruiting
NCT07464756 — SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer · Phase 2 · not yet recruiting
NCT07482826 — Full-Endoscopic Decompression vs. Endoscopic Lumbar Fusion for Middle-Aged and Older Adults With Spinal Stenosis · NA · not yet recruiting
NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03090516 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital with Nanjing Medical University
Last refreshed: 7 August 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03090516.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing